Keywords: novartis/genentech, xolair, approved, novartis, genentech, anti-immunoglobulin, e-based

Novartis/Genentech's Xolair approved

Article | 24 June 2002

Novartis and Genentech's anti-immunoglobulin E-based therapy, Xolair(omalizumab), has been approved for marketing in Australia, its first market, for treating ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Genentech

Novartis

Go to company listing

Related Drugs

Omalizumab

Xolair

Go to drug listing